

OMB APPROVAL	
OMB Number:	3235-0287
Expires:	December 31, 2014
Estimated average burden hours per response:	0.5

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>SIGMA TAU INTERNATIONAL SA</u> (Last) (First) (Middle) (Street) (City) (State) (Zip)	2. Issuer Name and Ticker or Trading Symbol <u>QUESTCOR PHARMACEUTICALS INC</u> [QSC]	5. Relationship of Reporting Person(s) to Issuer (Check all applicable) Director <input checked="" type="checkbox"/> 10% Owner Officer (give title below) Other (specify below)
	3. Date of Earliest Transaction (Month/Day/Year) <u>06/12/2003</u>	
	4. If Amendment, Date of Original Filed (Month/Day/Year)	

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned

1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price			
Common Stock, no par value per share	06/12/2003	06/12/2003	s		10,000	D	1.15	16,441,375	D ⁽¹⁾	

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)

1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)	8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)					

1. Name and Address of Reporting Person*
SIGMA TAU INTERNATIONAL SA
 (Last) (First) (Middle)
 (Street)
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
SIGMA TAU FINANZIARIA SPA
 (Last) (First) (Middle)
 (Street)
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
CAVAZZA CLAUDIO
 (Last) (First) (Middle)
 (Street)
 (City) (State) (Zip)

1. Name and Address of Reporting Person*
CAVAZZA PAOLO

(Last)	(First)	(Middle)

(Street)		

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<u>DEFIANTE FARMACEUTICA LDA</u>		

(Last)	(First)	(Middle)

(Street)		

(City)	(State)	(Zip)
1. Name and Address of Reporting Person*		
<u>APTAFIN S P A</u>		

(Last)	(First)	(Middle)

(Street)		

(City)	(State)	(Zip)

Explanation of Responses:

1. Shares solely owned by Sigma-Tau International S.A. (f/k/a Sigma-Tau Finance Holding S.A.). Sigma-Tau Finanziaria S.p.A. owns 100% of the capital stock of Sigma-Tau International S.A. and 58% of the capital stock of Defiante Farmaceutica L.d.A. Sigma-Tau International S.A. owns 42% of the capital stock of Defiante Farmaceutica L.d.A. Claudio Cavazza owns, directly and indirectly, 60% of Sigma-Tau Finanziaria S.p.A. and Paolo Cavazza owns, directly and indirectly, 40% of Sigma-Tau Finanziaria S.p.A. Paolo Cavazza also owns, directly and indirectly, 100% of Aptafin S.p.A.

[Antonio Nicolai, Attorney-in-fact for Mauro Bove, Director, on behalf of Sigma-Tau International S.A.](#) [06/16/2003](#)

[Antonio Nicolai, Attorney-in-fact for Mario Artali, Managing Director, on behalf of Sigma-Tau Finanziari S.p.A.](#) [06/16/2003](#)

[Antonio Nicolai, Attorney-in-fact for Claudio Cavazza](#) [06/16/2003](#)

[Antonio Nicolai, Attorney-in-fact for Paolo Cavazza](#) [06/16/2003](#)

[Antonio Nicolai, Attorney-in-fact for Raffele Sanguigni, Director, on behalf of Defiante Farmaceutica L.D.A.](#) [06/16/2003](#)

[Antonio Nicolai, Attorney-in-fact for Piero Belletti, Managing Director, on behalf of Aptafin S.p.A.](#) [06/16/2003](#)

** Signature of Reporting Person Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).

** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.